<DOC>
	<DOCNO>NCT01585649</DOCNO>
	<brief_summary>This Phase I , open label study aim assess pharmacokinetics , pharmacodynamics , efficacy , safety , tolerability single injection XM22 child Ewing family tumor rhabdomyosarcoma schedule receive chemotherapy ( CTX )</brief_summary>
	<brief_title>PK/PD XM22 Children With Ewing Family Tumors Rhabdomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<criteria>Male female child adolescent age 2 &lt; 18 year Written inform consent provide parent ( ) /legal representative ( ) pediatric patient patient 's assent appropriate Able understand and/or follow study instruction alone parental assistance Diagnosed Ewing family tumor Rhabdomyosarcoma Scheduled receive 1 follow CTX regimen ( inpatient outpatient ) For Ewing family tumor : vincristine/ifosfamide/doxorubicin/etoposide ( VIDE ) ; concomitant sodium 2mercaptoethane sulfonate ( MESNA ) accord local standard vincristine/doxorubicin/cyclophosphamide alternate ifosfamide/etoposide ( VDC/IE ) ; concomitant MESNA treatment accord local standard For rhabdomyosarcoma : vincristine/actinomycin/cyclophosphamide ( VAC ) vincristine/doxorubicin/cyclophosphamide alternate ifosfamide/etoposide ( VDC/IE ) ; concomitant MESNA treatment accord local standard Chemotherapynaïve Body weight ≥15 kg White blood cell ( WBC ) count &gt; 2.5 x 109/L , absolute neutrophil count ( ANC ) ≥1.5 x 109/L , platelet count ≥100 x 109/L ( screen prior CTX ) For patient age ≥12 year , Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ( See Appendix A . ) Fertile patient ( male female ) must use highly reliable contraceptive measure ( i.e . two follow : oral contraception , implant , injection , barrier contraception , intrauterine device , vasectomized/sterilized partner , sexual abstinence ) . For purpose study , fertile female patient female patient experience menarche undergone tubal ligation . Female patient attain menarche must negative urine pregnancy test screen visit . Previous exposure filgrastim , pegfilgrastim lenograstim GCSFs clinical development within 6 month prior XM22 administration Known hypersensitivity filgrastim , pegfilgrastim lenograstim GCSF clinical development History congenital neutropenia cyclic neutropenia Any illness condition opinion Investigator may affect safety patient evaluation study endpoint Pregnant nursing woman Fertile patient agree use highly reliable contraceptive measure entire duration study Prior bone marrow stem cell transplant , prior radiation ≥25 % bone marrow ( e.g . whole pelvic radiation ) reason , therapeutic radiation within 3 week prior XM22 dose Ongoing active infection history infectious disease within 2 week prior screen visit Treatment lithium screening plan study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>